
Samrat Pharmachem Ltd is Rated Sell
2026-10-26 10:10:02Samrat Pharmachem Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with the latest insights into its performance and outlook.
Read More
Samrat Pharmachem Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
2026-10-15 08:06:48Samrat Pharmachem Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 14 Oct 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s micro-cap status and challenging financial trends continue to weigh on its outlook, but recent technical signals suggest a cautiously improved market sentiment.
Read More
Samrat Pharmachem Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks
2026-10-12 08:03:49Samrat Pharmachem Ltd has been downgraded from a Sell to a Strong Sell rating as of 09 Oct 2026, reflecting deteriorating technical indicators and weak fundamental performance. The pharmaceutical micro-cap’s Mojo Score has declined to 23.0, signalling heightened risk for investors amid flat financial results and a challenging market environment.
Read More
Samrat Pharmachem Ltd is Rated Strong Sell
2026-10-11 10:10:27Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 October 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Read More
Samrat Pharmachem Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change
2026-09-30 08:08:49Samrat Pharmachem Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Sep 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s recent performance and valuation metrics continue to raise concerns, but improved technical trends have prompted a more favourable outlook from analysts.
Read More
Samrat Pharmachem Ltd is Rated Strong Sell
2026-09-25 10:10:21Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 September 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Samrat Pharmachem Ltd is Rated Sell by MarketsMOJO
2026-09-04 10:11:07Samrat Pharmachem Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Aug 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 September 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
18-Nov-2026 | Source : BSENewspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended 30th September 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th November 2026
14-Nov-2026 | Source : BSEThe Board of Directors considered and adopted the unaudited financial results for the quarter ended September 30 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
13-Oct-2026 | Source : BSECertificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th September 2026.
Corporate Actions
No Upcoming Board Meetings
Samrat Pharmachem Ltd has declared 10% dividend, ex-date: 18 Sep 25
No Splits history available
No Bonus history available
No Rights history available